Merck Eshmuno P anti-A and anti-B chromatography resins
Merck has launched the Eshmuno P anti-A and Eshmuno P anti-B affinity chromatography resins, specifically designed to remove anti-A and anti-B isoagglutinin antibodies during the manufacturing of plasma-derived immunoglobulin (Ig) therapies.
Trace amounts of anti-A and anti-B antibodies in plasma-derived Ig can lead to serious and sometimes fatal haemolytic events in patients undergoing plasma-based treatment. The introduction of chromatographic steps using Eshmuno P resins to deplete anti-A and anti-B antibodies is expected to reduce patient risk for adverse medical events associated with plasma-derived Ig therapies. This enhanced patient safety is achieved without negatively impacting process economics by re-using the resins for at least 200 cycles, with acid or alkaline cleaning, without loss of performance.
The resins are manufactured using a combination of Merck’s base matrix technology and a novel synthetic approach. The resins are released by an innovative test method to evaluate performance with less variability compared with classical agglutination methods, according to the company.
Merck’s chromatography resins are designed for efficient bioprocessing purification and are extensively used in commercial processes. The resins can be used to support plasma purification processes while minimising operational costs and time to clinic.
Original Article: Merck Eshmuno P anti-A and anti-B chromatography resins
